LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Aktien・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Geschlossen

BrancheGesundheitswesen

215.17 -1.26

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

213.19

Max

216.59

Schlüsselkennzahlen
By Trading Economics
Einkommen	-22M -61M
Verkäufe	56M 214M
Gewinnspanne	-28.549
Angestellte	1,017
EBITDA	-56M -53M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+31.78% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. Apr. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.7B 14B
Vorheriger Eröffnungskurs	216.43
Vorheriger Schlusskurs	215.17

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

157.66 / 167.29 Unterstützung & Widerstand

Ascendis Pharma A-S ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Feb. 2026, 16:32 UTC

Ergebnisse

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

14. Feb. 2026, 22:02 UTC

Ergebnisse

Looking for Dividends? Consider Europe. -- Barrons.com

14. Feb. 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. Feb. 2026, 21:57 UTC

Ergebnisse

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. Feb. 2026, 21:20 UTC

Ergebnisse

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13. Feb. 2026, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13. Feb. 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. Feb. 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13. Feb. 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13. Feb. 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13. Feb. 2026, 19:51 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. Feb. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. Feb. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. Feb. 2026, 19:29 UTC

Ergebnisse

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13. Feb. 2026, 18:18 UTC

Akquisitionen, Fusionen, Übernahmen

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13. Feb. 2026, 17:52 UTC

Ergebnisse

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13. Feb. 2026, 17:16 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. Feb. 2026, 17:10 UTC

Akquisitionen, Fusionen, Übernahmen

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13. Feb. 2026, 16:59 UTC

Ergebnisse

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13. Feb. 2026, 16:39 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13. Feb. 2026, 16:11 UTC

Ergebnisse

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13. Feb. 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13. Feb. 2026, 15:54 UTC

Ergebnisse

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13. Feb. 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13. Feb. 2026, 15:01 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13. Feb. 2026, 15:00 UTC

Ergebnisse

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13. Feb. 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13. Feb. 2026, 14:44 UTC

Ergebnisse

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13. Feb. 2026, 14:22 UTC

Market Talk

Ergebnisse

Global Energy Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Ascendis Pharma A-S ADR Prognose

Kursziel

By TipRanks

31.78% Vorteil

12-Monats-Prognose

Durchschnitt 287.42 USD 31.78%

Hoch 342 USD

Tief 250 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Ascendis Pharma A-S ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Ascendis Pharma A-S ADR – Dist abgegeben haben.

Technischer Score

By Trading Central

157.66 / 167.29Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.